This is Not the End – A Survivor’s Story
A story about a cancer survivor recently appeared in the Washington Post: “This is not the end; Using immunotherapy and a genetic glitch to give cancer patients hope”. The story is about a young [...]
A story about a cancer survivor recently appeared in the Washington Post: “This is not the end; Using immunotherapy and a genetic glitch to give cancer patients hope”. The story is about a young [...]
American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR). ASCO plans should increase patient access to off-label drugs and match patients with [...]
Some stomach GISTs smaller than 2 cm may pose more risk than previously thought according to a new report from China.
ASCO features many updates on GIST trials. Promising results for the immunotherapy approach to treating cancer dominated the annual conference of the ASCO and represent one of the biggest developments in cancer research since the advent [...]
Jonathan Fletcher and Sebastian Bauer of the LRG’s Research Team were among the authors in a study to be published in Cancer Research that examined the relationship between GIST and the expression of the gene DOG1.
The LRG research team meets four times a year, with at least one in-person meeting per year. This year, the team held its in-person meeting at the LRG office in New Jersey March 22-24, 2013.
Join our Tissue Bank - Help the LRG in the search for a cure. Wildtype GIST tissue is needed for a current LRG Research Team project. If you or a loved one are a wildtype GIST patient, please help the LRG Research Team in its search for the cure by donating your tissue.
First report of a GIST patient responding to a BRAF inhibitor. Dr. Gerald Falchook and colleagues at MD Anderson Cancer Center provided the first report of a GIST patient responding to a BRAF inhibitor. The BRAF gene is frequently mutated in melanoma and BRAF inhibitors provide one of the most important therapies available for melanoma patients
Treatment guidelines for GIST are established by experts to ensure that patients receive adequate care and appropriate therapies.
Since we have gotten a number of questions about Gleevec (imatinib) plasma levels and testing, I think it’s time to revisit the subject, especially for newer members. Since this is a very complex subject, this may take a few emails and a few days.